Mylan Stretches Game Clock, Adds To Costs For Perrigo Takeover Play
This article was originally published in The Tan Sheet
Executive Summary
Perrigo says Mylan shows “desperation” in targeting approval by 50% of its shareholders rather than the 80% approval it initially stated in its regulatory filing. A 50% threshold means Mylan would pay more in interest to lenders because it would be required to continue its takeover attempt longer than initially planned.
You may also be interested in...
Perrigo Gains 180-Day Exclusivity With ANDA Approval For Omeprazole Magnesium PPI
Perrigo receives approval for its ANDA for a Prilosec OTC equivalent and another for a generic of Advil Fast Relief. The firm includes those products in its outlook for $1 billion in new product sales over three years.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.